In the cystoscopic follow-up of non-muscle-invasive transitional cell carcinoma, NMP-22 works for high grades, but unreliable in low grades and upper urinary tract tumors

dc.contributor.author	Coskuner, E.
dc.contributor.author	Cevik, I.
dc.contributor.author	Ozkan, A.
dc.contributor.author	Dillioglugil, O.
dc.contributor.author	Akdas, A.
dc.date.accessioned	2021-12-21T08:41:56Z
dc.date.available	2021-12-21T08:41:56Z
dc.date.issued	2012
dc.identifier.issn	3011623
dc.identifier.uri	https://doi.org/10.1007/s11255-012-0144-x
dc.identifier.uri	http://dspace.yeniyuzyil.edu.tr:8080/xmlui/handle/20.500.12629/1555
dc.description.abstract	Introduction and objectives Two percent of the bladder non-muscle-invasive (NMI) transitional cell carcinomas (TCC) are associated with upper urinary tract (UUT) TCC. We evaluated the role of nuclear matrix protein-22 (NMP-22) (BladderChek®) test in the d
dc.language.iso	English
dc.title	In the cystoscopic follow-up of non-muscle-invasive transitional cell carcinoma, NMP-22 works for high grades, but unreliable in low grades and upper urinary tract tumors
dc.type	Article
dc.relation.journal	International Urology and Nephrology
dc.identifier.issue	3
dc.identifier.startpage	793
dc.identifier.endpage	798
dc.identifier.volume	44
dc.identifier.doi	10.1007/s11255-012-0144-x
dc.relation.issue	3
dc.relation.volume	44